Unlocking new potential: Rationale and evidence for dual EZH2/AR inhibition in mCRPC
touchTALKS for touchONCOLOGY
Listen to Dr Teresa Alonso-Gordoa, as she evaluates the latest data on dual EZH2/AR inhibition in mCRPC and explores how emerging evidence could influence clinical decision-making in the future.
The expert
Dr. Teresa Alonso-Gordoa - Hospital Universitario Ramón y Cajal, Madrid, Spain
This touchPODCAST is for HCPs outside of the UK only.
This activity is funded by an independent medical education grant from Pfizer.
This activity is provided by touchIME.
touchIME is an EBAC® accredited provider.
For further information visit our website: www.touchONCOLOGY.com
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.